Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders

Medicine & Life Sciences

• Multiple Sclerosis 100%
• Neuromyelitis Optica 91%
• Health Care Outcome Assessment 74%
• Optical Coherence Tomography 45%
• Ocular Vision 38%
• Myelin-Oligodendrocyte Glycoprotein 32%
• Smooth Pursuit 31%
• Afferent Pathways 31%
• Aquaporin 4 30%
• Eye Abnormalities 30%
• Remyelination 30%
• Informatics 28%
• Visual Pathways 28%
• Saccades 26%
• Neuroprotection 23%
• Visual Fields 22%
• Wounds and Injuries 21%
• Visual Acuity 19%
• Cost-Benefit Analysis 19%
• Therapeutics 18%
• Technology 14%
• Clinical Trials 14%
• Quality of Life 14%
• Antibodies 12%